Literature DB >> 17512352

The management of recurrent ovarian cancer.

Ronald M Bukowski1, Robert F Ozols, Maurie Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17512352     DOI： 10.1053/j.seminoncol.2007.03.012

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  35 in total

1.  Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Masami Hayashi; Kenjiro Sawada; Kimihiko Ito; Yoshito Terai; Yukihiro Nishio; Andres J Klein-Szanto; Robert A Burger; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

Review 2.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

3.  Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Authors:  Jürgen Grünberg; Dennis Lindenblatt; Holger Dorrer; Susan Cohrs; Konstantin Zhernosekov; Ulli Köster; Andreas Türler; Eliane Fischer; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-24       Impact factor: 9.236

4.  Web-based symptom management for women with recurrent ovarian cancer: a pilot randomized controlled trial of the WRITE Symptoms intervention.

Authors:  Heidi S Donovan; Sandra E Ward; Susan M Sereika; Judith E Knapp; Paula R Sherwood; Catherine M Bender; Robert P Edwards; Margaret Fields; Renee Ingel
Journal:  J Pain Symptom Manage       Date:  2013-09-07       Impact factor: 3.612

5.  Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.

Authors:  Fang Fang; Horacio Cardenas; Hao Huang; Guanglong Jiang; Susan M Perkins; Chi Zhang; Harold N Keer; Yunlong Liu; Kenneth P Nephew; Daniela Matei
Journal:  Cancer Res       Date:  2017-12-11       Impact factor: 12.701

6.  Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment.

Authors:  Elizabeth M Freeburg; Alicia A Goyeneche; Carlos M Telleria
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

7.  Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.

Authors:  Rui-Lan Huang; Fei Gu; Nameer B Kirma; Jianhua Ruan; Chun-Liang Chen; Hui-Chen Wang; Yu-Ping Liao; Cheng-Chang Chang; Mu-Hsien Yu; Jay M Pilrose; Ian M Thompson; Hsuan-Cheng Huang; Tim Hui-Ming Huang; Hung-Cheng Lai; Kenneth P Nephew
Journal:  Epigenetics       Date:  2013-05-10       Impact factor: 4.528

Review 8.  Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

Authors:  Natalie J Carter; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.

Authors:  Gisele A Sarosy; Mahrukh M Hussain; Michael V Seiden; Arlan F Fuller; Najmosama Nikrui; Annekathryn Goodman; Lori Minasian; Eddie Reed; Seth M Steinberg; Elise C Kohn
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860

Review 10.  The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review.

Authors:  Aditi Bhatt; Olivier Glehen
Journal:  Indian J Surg Oncol       Date:  2016-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.